undamentalytics Newsletter
Sign in

Evolus, Inc. cash flow statement

In fiscal 2025, Evolus, Inc.'s operations generated −$42.3m of cash; it spent $3.4m on capital projects, leaving free cash flow of −$45.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−26−93−58−33−85−34−18−42−15
Depreciation and amortisation047645587
Stock-based pay71011101116222121
Capital spending001020133
Free cash flow−26−94−59−34−87−34−19−46−18
Free cash flow after stock pay−33−103−69−43−97−51−42−66−39
Shares issued68730—00510—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: EOLS vs XERSEOLS vs HROWEOLS vs IRWD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Evolus, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evolus, Inc.